Patients treated with semaglutide 7.2 mg achieved a 20.7% weight loss after 72 weeks compared with a reduction of 17.5% with semaglutide 2.4 mg (Wegovy ... phase IIIb STEP UP trial showed.

Today was supposed to mark the beginning of the end for cheaper, knockoff versions of hot weight-loss drugs. The Food and Drug Administration wants bulk production of the copycats to stop ...

After 12 weeks, weight loss with the drug was 13% of body weight, compared to 1% with placebo, which the company said was around twice the level achieved with Wegovy ... in the STEP 9 trial.

The Danish company aims to position CagriSema as a more potent successor to its popular obesity drug Wegovy ... or about $8.4 billion, in 2024. But earlier trial results in people without diabetes ...

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide ... in a 2023–24 randomized clinical trial backed by Lilly.

Novo Nordisk's STEP trial programme for Wegovy revealed an average reduction in body weight of around 12%, suggesting greater potency for Lilly's dual-acting drug – with the usual caveat about ...

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo ...

Investors and analysts have awaited the readout of Novo's REDEFINE 2 late-stage trial, hoping it would show that next-generation CagriSema was a more potent successor to Novo's blockbuster Wegovy ...